On September 9, 2025, the White House and the U.S. Food and Drug Administration (FDA) announced extensive reforms to curb deceptive direct-to-consumer (DTC) pharmaceutical advertising, signaling a dramatic shift toward more aggressive enforcement.

 

Overview
On September 9, 2025, the White House directed the Department of Health and Human Services (HHS) and FDA to restore transparency and accountability in prescription drug advertising. In response, FDA sent thousands of letters demanding the removal of misleading ads and approximately 100 cease-and-desist letters to companies running deceptive campaigns. The agency also announced new rulemaking to close the “adequate provision” loophole, which the agency claims has enabled drug manufacturers to conceal critical safety risks in broadcast and digital ads.

 

FDA Is Ramping Up Deceptive DTC Drug Advertisement Enforcement

In very direct terms, FDA put the pharmaceutical industry on notice that the agency will proactively seek to combat violative deceptive DTC drug ads. FDA warned that after years of lax enforcement—with FDA dramatically reducing the number of warning letters related to DTC drug advertising in recent years—pharmaceutical manufacturers are now on notice that FDA intends to aggressively deploy its available enforcement tools, including AI and tech-enabled enforcement tools to proactively monitor and review DTC drug ads.

 

Key Takeaways

  • Stronger Enforcement Posture: FDA has issued cease-and-desist letters at an unprecedented scale and pledges to maintain robust monitoring of DTC drug ads going forward.
  • Rulemaking Ahead: The agency will initiate rulemaking aimed at closing loopholes allowing drug makers to conceal risk information from patients in advertising.
  • Digital & Social Media Focus: FDA specifically highlighted concerns with influencer promotions and digital ads that blur the lines between evidence-based information and promotional material.
  • Compliance Expectations: FDA directed drug manufacturers to remove any noncompliant advertising and bring all promotional communications into compliance.

 

Next Steps for Industry

The pharmaceutical industry should anticipate increased FDA scrutiny. Now is the time to review your company’s advertising and promotional review policies and procedures to ensure that they align with FDA’s DTC drug advertising requirements and that current product labeling and advertisements comply with FDA requirements.

 

We will continue to monitor this development as well as other FDA regulatory developments related to drugs, medical devices, biologics, foods, and dietary supplements. Please contact us if we can be of assistance with this or similar FDA regulatory issues.

 

Kirton McConkie provided this article as a service to clients and friends of the firm. It is for informational purposes only and should not be construed as legal advice. If you have questions about how these developments may affect your organization, please contact Seth Olson, Joseph Brubaker, or Jonathan Bench.